Substituted indoles as HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent evaluation (WO2015044928)

References

• Kohlstaedt L, Wang J, Friedman J, et al. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992;256:1783–1790.
   PubMed Web of Science ®Google Scholar
• Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res. 2008;134:147–156.
   PubMed Web of Science ®Google Scholar
• Asahchop EL, Wainberg MA, Sloan RD, et al. Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chem Other. 2012;56:5000–5008.
   PubMed Web of Science ®Google Scholar
• Reynolds C, de Koning CB, Pelly SC, et al. In search of a treatment for HIV-current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Chem Soc Rev. 2012;41:4657–4670.
   PubMed Web of Science ®Google Scholar
• Jayaweera D, Dilanchian P. New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data. Expert Opin Pharmacother. 2012;13:2601–2612.
   PubMed Web of Science ®Google Scholar
• Rawal RK, Murugesan V, Katti SB. Structure-activity relationship studies on clinically relevant HIV-1 NNRTIs. Curr Med Chem. 2012;19:5364–5380.
   PubMed Web of Science ®Google Scholar
• Sweeney ZK, Klumpp K. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data. Curr Opin Drug Discov Devel. 2008;11:458–470.
   PubMedGoogle Scholar
• Zhan P, Pannecouque C, De Clercq E, et al. Anti-HIV drug discovery and development: current innovations and future trends. J Med Chem. 2015. doi: 10.1021/acs.jmedchem.5b00497.
   Google Scholar
• Croxtall JD. Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection. Drugs. 2012;72:847–869.
   PubMed Web of Science ®Google Scholar
• Schafer JJ, Short WR. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review. Antivir Ther. 2012;17:1495–1502.
   PubMed Web of Science ®Google Scholar
• Li D, Zhan P, De Clercq E, et al. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. J Med Chem. 2012;55:3595–3613.
   PubMed Web of Science ®Google Scholar
• Zhan P, Chen X, Li D, et al. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev. 2013;33 Suppl 1:E1–E72.
   PubMed Web of Science ®Google Scholar
• Jiang HX, Zhuang DM, Huang Y, et al. Design, synthesis, and biological evaluation of novel trifluoromethylindoles as potent HIV-1NNRTIs with an improved drug resistance profile. Org Biomol Chem. 2014;12:3446–3458.
   PubMed Web of Science ®Google Scholar
• Regina GL, Coluccia A, Piscitelli F, et al. Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity. J Med Chem. 2007;50:5034–5038.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Wolkenberg SE, Sanderson PE, et al. Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs). Bioorg Med Chem Lett. 2008;18:554–559.
   PubMed Web of Science ®Google Scholar
• Piscitelli F, Coluccia A, Brancale A, et al. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. J Med Chem. 2009;52:1922–1934.
   PubMed Web of Science ®Google Scholar
• La Regina G, Coluccia A, Brancale A, et al. Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide. J Med Chem. 2011;54:1587–1598.
   PubMed Web of Science ®Google Scholar
• La Regina G, Coluccia A, Brancale A, et al. New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors. J Med Chem. 2012;55:6634–6638.
   PubMed Web of Science ®Google Scholar
• Famiglini V, La Regina G, Coluccia A, et al. New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors. Eur J Med Chem. 2014;80:101–111.
   PubMed Web of Science ®Google Scholar
• Famiglini V, La Regina G, Coluccia A, et al. Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors. J Med Chem. 2014;57:9945–9957.
   PubMed Web of Science ®Google Scholar
• Hassam M, Basson AE, Liotta DC, et al. Novel cyclopropyl-indole derivatives as HIV non-nucleoside reverse transcriptase inhibitors. ACS Med Chem Lett. 2012;3:470–475.
   PubMed Web of Science ®Google Scholar
• Müller R, Mulani I, Basson AE, et al. Novel indole based NNRTIs with improved potency against wild type and resistant HIV. Bioorg Med Chem Lett. 2014;24:4376–4380.
   PubMed Web of Science ®Google Scholar
• The Regents Of Stellenbosch University. Substituted indoles and their use as HIV-1 non-nucleoside reverse transcriptase inhibitors. WO2015044928. 2015.
   Google Scholar
• Rouf A, Taneja SC. Synthesis of single-enantiomer bioactive molecules: a brief overview. Chirality. 2014;26:63–78.
   PubMed Web of Science ®Google Scholar
• Shen Q, Wang L, Zhou H, et al. Stereoselective binding of chiral drugs to plasma proteins. Acta Pharmacol Sin. 2013;34:998–1006.
   PubMed Web of Science ®Google Scholar
• Priet S, Roux L, Saez-Ayala M, et al. Enzymatic synthesis of acyclic nucleoside thiophosphonate diphosphates: effect of the α-phosphorus configuration on HIV-1 RT activity. Antiviral Res. 2015;117:122–131.
   PubMed Web of Science ®Google Scholar
• Venkatachalam TK, Mao C, Uckun FM. Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives. Biochem Pharmacol. 2004;67:1933–1946.
   PubMed Web of Science ®Google Scholar
• Radzio J, Sluis-Cremer N. Stereo-selectivity of HIV-1 reverse transcriptase toward isomers of thymidine-5ʹ-O-1-thiotriphosphate. Protein Sci. 2005;14(7):1929–1933.
   PubMed Web of Science ®Google Scholar
• Gao HQ, Boyer PL, Sarafianos SG, et al. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J Mol Biol. 2000;300:403–418.
   PubMed Web of Science ®Google Scholar
• Rotili D, Samuele A, Tarantino D, et al. 2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies. J Med Chem. 2012;55:3558–3562.
   PubMed Web of Science ®Google Scholar
• Gu SX, Li ZM, Ma XD, et al. Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors. Eur J Med Chem. 2012;53:229–234.
   PubMed Web of Science ®Google Scholar
• Radi M, Maga G, Alongi M, et al. Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants. J Med Chem. 2009;52:840–851.
   PubMed Web of Science ®Google Scholar
• Alexandre FR, Amador A, Bot S, et al. Synthesis and biological evaluation of aryl-phospho-indole as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. J Med Chem. 2011;54(1):392–395.
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Li Z, et al. Design strategies of novel NNRTIs to overcome drug resistance. Curr Med Chem. 2009;16:3903–3917.
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Li Z. Recent advances inthe discovery and development of novel HIV-1 NNRTI platforms: 2006–2008 update. Curr Med Chem. 2009;16:2876–2889.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang L, Tian Y, et al. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011-2014). Expert Opin Ther Pat. 2014;24:1199–1227.
   PubMed Web of Science ®Google Scholar